Sartorius Stedim Biotech launches ambr 15 bioreactor system with Nova BioProfile FLEX2 integration
QbD studies in upstream processing more rapidly performed.
Sartorius Stedim Biotech (SSB) has announced that the ambr 15 automated micro bioreactor system combined with a Nova Biomedical (Nova) BioProfile FLEX2 automated cell culture analyser is on show for the first time at the Cell Line Development & Engineering Conference in San Diego, California. This newly integrated system, which is a first from SSB and Nova’s successful collaboration, enables rapid at-line sample collection and analysis of massive quantities of key cell culture data.
SSB and Nova have collaborated to seamlessly integrate the software interface that controls the ambr 15 workstation for automated parallel processing of 24 or 48 single-use bioreactors (10–15 mL working volume) with the cell culture analysis capabilities of the innovative BioProfile FLEX2. The combined system provides a unique tool to simultaneously run, sample and analyse a massive number of cell culture conditions during cell line and media development by Design of Experiments (DoE).
Combining the ambr 15 and the BioProfile FLEX2 enables fully integrated automatic sample transfer, analysis and automated feedback control in each single-use ambr 15 bioreactor. This allows collection of enormous quantities of cell culture data, including total and viable cell density, viability, cell diameter, pH, PCO2, PO2, glucose, lactate, glutamine, glutamate, ammonium, Na+, K+, Ca++ and osmolality, which can be sampled and measured with a complete cycle time of just 6–7 minutes. The ambr 15 software simultaneously acquires the BioProfile FLEX2 data set and processes it, for example, by performing complex in-run calculations of how much feed volume to automatically add during a run. This saves time by significantly increasing the amount of consistent clone selection, media development and culture parameter data that a scientist can generate per run.
“We have combined two highly innovative technologies. Our successful partnership with Nova has delivered complete at-line analytics capabilities for our ambr 15 platform. Utilizing these integrated systems will support scientists to more easily run full QbD studies, without causing a sampling bottleneck or needing additional staff resources. The new system will optimize their process productivity, as well as the quality of their biologics,” stated Dr Barney Zoro, ambr Product Manager at SSB.
“There is a significant demand for fully automated cell culture analysis of small-volume culture systems like the Sartorius ambr micro bioreactor system,” said Matthew McRae, Biotechnology Sales Product Line Manager at Nova. “We’re excited to have worked with SSB on this integration program because our BioProfile FLEX2 with maintenance-free sensors provides rapid analysis of key cell culture tests using just 265 microliters of sample. As a result, this analyzer is a highly complementary addition to the ambr 15 while maintaining the flexibility and modularity of the first-generation BioProfile FLEX analyser.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance